Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Tris-CAR-T by Tasly Pharmaceutical Group for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Tris-CAR-T is under clinical development by Tasly Pharmaceutical Group and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According...